Ruti Aga's six-year ban: the sentence was carried by a forged prescription, not by the drug

The clinic printed on the prescription did not exist. The person who wrote it was family, and appeared on no medical register. The pad, said to have been lifted from a former workplace, was disowned by that clinic in plain words. The Athletics Integrity Unit checked the same sheet of paper three ways — against the clinic's existence, against the writer's registration, against the pad's claimed provenance. Three times the paper failed.

I was not at the Chinese half marathon in March where the sample was taken. I was in London, reading a statement. What stopped me was not the positive test. It was a piece of handwriting someone had produced on the assumption that nobody would bother to verify it.

Ruti Aga is an Ethiopian marathoner, thirty-two years old. Her record carries the 2026 Tokyo Marathon title and three runner-up finishes at World Marathon Majors. That is the tier where silverware and income sit on the same staircase — a Tokyo winner gets next season's invitations and appearance fees automatically, whether or not she ever converts at a global championship. What was announced here is this: methylprednisolone in an in-competition sample after she won a half marathon in China in March; a knee injury offered as the explanation; the prescription found to be forged; and a six-year ban, dated from 10 September, the same date her provisional suspension began.

What the statement does not contain matters just as much. No race time. No field depth. No year, and no stated end date for the ban. And the largest silence of all — the scope of disqualification is not described. Standard AIU practice voids the result and prize money from the competition where the sample was collected, so it is reasonable to assume the March win no longer stands. The 2026 Tokyo title does not fall automatically; that would require a finding reaching back to that season, and the statement contains none.

There is a technical error in the reporting of this case that needs correcting, because the whole matter turns on it. Accounts describing methylprednisolone as a prohibited steroid are telling half the story. Methylprednisolone is not an anabolic steroid; it is a glucocorticoid, class S9 on the WADA Prohibited List, and it is prohibited in-competition only, by injection, oral or rectal route. A therapeutic injection into a runner's knee out of competition is not, by itself, unlawful. It becomes a violation when residue is still present on race day.

That changes the shape of the defence entirely. The question is not whether a steroid was taken. It is by which route, at what dose, and how many days before the gun. In road racing the in-competition testing window opens at 23:59 the night before the race, so an injection given days earlier can still be caught. A clean pathway existed: a documented treatment, a correctly calculated washout, or a therapeutic use exemption where needed. None of the three appears to have happened. And when a prescription is manufactured instead of a genuine record produced, the message becomes legible.

Look at the arithmetic. Two years for the presence violation, four for tampering with documents and testimony — six in total. The two-year figure indicates the panel treated the substance as specified, without a finding that the intent was performance enhancement. The four-year figure indicates it treated the tampering as fully culpable. The two-plus-four is the most informative number in the file: the panel declined the no-significant-fault reduction that would otherwise have shortened the presence sanction.

Backdating to 10 September is procedural, not lenient. Time served under provisional suspension counts against the ban, so the athlete gains nothing in real terms. Six years at thirty-two puts a return at roughly thirty-eight — and in Ethiopian women's marathon running, where a 2:18 performer is not automatically selectable, a thirty-eight-year-old returning with a doping record has no route back.

The root cause is the knee. Chronic knee synovitis and corticosteroid injection for it are ordinary sports medicine in distance running. In 2026 at Bhubaneswar I watched Neeraj Chopra's javelin with his right elbow strapped, and I was watching the elbow more than the distance. I spoke to an AFI biomechanist and a physio from NIS Patiala, and what I carried away was this: a body's problem is frequently the problem of the system around it, not of the athlete's character. Here the system's truth is stark — no credentialed team physio, no exemption process, no washout calculation. When no legitimate piece of paper existed, a piece of paper was manufactured instead.

Compare the structures. In January 2026 I audited a Chelsea medical for a player with a hamstring history; the transfer-window deadline is what decides how much risk a club will discount. There is an entire file system in that world. In 2026 at Patiala I followed Hima Das's return from a back injury through the empty-stadium shutdown, no races on the calendar; SAI physios adjusted her return-to-run protocol and I explained load spikes to her family on a video call in plain language. A framework existed. Return-to-run is a series of small permissions, and behind each permission should sit a document. Aga had no such chain.

The economics sit underneath all of it. China's label-race circuit is the income tier between Majors for East African marathoners — good appearance fees, low racing risk. That same tier is now among the AIU's highest-yield testing grounds. The appearance-fee economy and the testing economy are colliding in the same races. Load is a story told in minutes, and I only transcribe it; here the minutes have been replaced by paperwork.

The counter-intuitive reading is that the drug did not deliver this sentence. The paper did. Had a genuine treatment existed with genuine records, a legitimate defence was open: route, timing and medical necessity, argued toward the no-fault end of the scale. The forged prescription closed the one door that worked. A document built to protect an athlete becomes the most damning exhibit against her.

Second, the framing error. Presenting methylprednisolone as a steroid is convenient, because it supplies a ready-made doping-culture narrative. There is no solid evidence that glucocorticoids improve endurance performance. Six years for a substance with no demonstrated marathon benefit, four of them for a document she created herself — that ratio is arguable, and it will be argued in the cases that follow.

Third, and this is what unsettles me most: the enforcement frontier has moved from detection to document verification. Athletes furthest from registered clinics, insurance and team doctors are the most exposed at that frontier. Let me mark my own distance here. I sit in London; I do not watch these training camps daily. The mechanism claims in this piece come from the AIU statement and from pharmacology, not from my own eyes on the ground. Where my archive is silent, I write the silence.

The forward question is not whether six years should have been two. It is why a thirty-two-year-old had nobody keeping the medical file on her knee. The next case is probably already running in a camp on the same informal network — and it will have no scan either. A credentialed physio cost less than six years. That sentence is the whole file.